An estimated 5 million South Africans now live with HIV/AIDS. National policy has focused on prevention; and antiretroviral ARV) medicines, which can prolong and improve quality of life for AIDS patients, have been prohibitively expensive. Photograph by Gideon Mendel
Report |

Sources and prices of selected drugs and diagnostics for people living with HIV/AIDS- Spanish version

Photograph by Gideon Mendel

A joint UNICEF, UNAIDS, WHO and MSF document providing market information to help procurement agencies make informed decisions on the source of drugs and to serve as the basis for negotiating affordable prices

Glossary v

1. Introduction 1

2. Access to quality HIV/AIDS drugs and diagnostics 4

3. Sources and prices of drugs 6

4. Variation in price between surveys 13

Annex I.
A. List of drugs by therapeutic group & manufacturers 14
B. Index of manufacturers 18
C. Country location of participating manufacturers 24
D. Geographical distribution of participating manufacturers 25

Annex II. WHO bulk procurement list for HIV tests, 2000 26

Annex III. Summary of main characteristics of seven CD4 T-cell enumeration technologies 29

Annex IV. Further reading, references and contacts 31

Annex V. Feedback and enquiry form 34


Table 1.
Anti-infective drugs 6
Antibacterials 6
Antifilarials 7
Antifungal drugs 7
Antihelminthics 8
Antiprotozoal drugs 8
Antivirals 8
Antiretrovirals 9

Table 2.
Antineoplastics 10
Cytotoxic drugs 10

Table 3.
Psychotherapeutic drugs 11
Drugs used in depressive disorders 11
Drugs used in generalized anxiety and sleep disorders 11

Table 4.
Analgesics 11
Opioid analgesics 11
Drugs used in the treatment of opioid dependence 12

Table 5.
Gastrointestinal drugs 12
Antacids and other antiulcer drugs 12
Antiemetic drugs 12
Laxatives 12

Table 6.
Variation in the price of ciprofloxacin and fluconazole between survey 13